Preclinical pharmacology of the new GLP-1 receptor agonist AVE0010.
Werner
U
U
Sanofi Aventis, R&D, TD Metabolism, Industriepark Höchst, Frankfurt, Germany. ulrich.werner@sanofi-aventis.com
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D016466:CHO Cells; D002352:Carrier Proteins / Q000627:therapeutic use*; D006224:Cricetinae; D003412:Cricetulus; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy / Q000235:genetics; D004305:Dose-Response Relationship, Drug; D000067757:Glucagon-Like Peptide-1 Receptor; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D051379:Mice; D010179:Pancreas / Q000187:drug effects; D010455:Peptides / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D018027:Receptors, Glucagon / Q000819:agonists*; D000067758:Glucagon-Like Peptide-2 Receptor
D001786:Blood Glucose; D002352:Carrier Proteins; D000067757:Glucagon-Like Peptide-1 Receptor; D007004:Hypoglycemic Agents; D010455:Peptides; D018027:Receptors, Glucagon; C000593833:GLP1R protein, human; C000593834:Glp1r protein, mouse; C000593835:Glp1r protein, rat; C479460:lixisenatide; D000067758:Glucagon-Like Peptide-2 Receptor